Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. As a first-in-class medication,… Read more










































Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. As a first-in-class medication, its precise analytical monitoring is vital for maintaining product quality and therapeutic efficacy. This category of reference standards includes the parent drug alongside a comprehensive suite of synthetic intermediates, process-related impurities, degradation products, and metabolites such as glucuronides and nitroso derivatives. Pharmaceutical laboratories utilize these high-quality compounds as essential benchmarks for impurity profiling, method validation, and stability testing. Additionally, stable isotope labelled compounds are available to provide internal standards for accurate quantification in complex bioanalytical studies. By using these rigorously characterized materials, researchers and quality control teams can ensure regulatory compliance and maintain the high standards required for the development and assessment of this important pulmonary therapeutic.